Related Experiment Video
Updated: Mar 9, 2026
06:24
Author Spotlight: Advancements in iPSCs and Genetic Disease Research
Published on: October 20, 2023
2.0K
Du-Huo-Ji-Sheng-Tang and its active component Ligusticum chuanxiong promote osteogenic differentiation and decrease
Jir-You Wang1, Wei-Ming Chen2, Che-Sheng Wen3
1Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC; Department of Orthopedics and Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Journal of Ethnopharmacology
|January 2, 2017
Summary
Du-Huo-Ji-Sheng-Tang (DHJST) and Ligusticum chuanxiong promote bone formation and delay aging in human mesenchymal stem cells. These findings suggest potential therapeutic benefits for postmenopausal osteoporosis by enhancing osteogenesis and reducing cellular senescence.
Area of Science:
- Biomedical Science
- Pharmacology
- Cell Biology
Background:
- Postmenopausal osteoporosis is a prevalent global bone disease.
- Limited information exists on herbal medicine effects on mesenchymal cell osteogenesis and senescence.
Purpose of the Study:
- Investigate Du-Huo-Ji-Sheng-Tang (DHJST) and Ligusticum chuanxiong effects on human mesenchymal stem cells (hMSCs).
- Assess impact on osteogenic differentiation and cellular aging.
Main Methods:
- hMSCs cultured in osteogenic media (OIM/DDOIM) for 1-2 weeks.
- Real-time PCR and Western blotting analyzed osteogenesis markers (BMP2, RUNX2) and signaling pathways (SMAD, ERK).
- Cellular senescence and growth curves evaluated aging effects.
Main Results:
- Ligusticum chuanxiong enhanced hMSC osteogenic activity and upregulated BMP-2 and RUNX2 via SMAD/ERK signaling.
- DHJST also promoted osteogenesis and activated SMAD/ERK signaling in dexamethasone-free conditions.
- Both DHJST and L. chuanxiong reduced hMSC senescence, delaying cellular aging.
Conclusions:
- DHJST and L. chuanxiong promote osteogenic activity in hMSCs.
- These agents effectively decrease hMSC senescence, mitigating cellular aging.
